Income Taxes (Tables)

12 Months Ended

Jan. 31, 2024

Income Tax Disclosure [Abstract]

Schedule of Income before Income Tax, Domestic and Foreign

The components of total loss from continuing operations before income taxes are as follows (in thousands):

	Fiscal Year Ended January 31,
	2024		2023		2022
US	$	14,328	$	(4,877)	$	19,486
Foreign	(174,480)		(170,453)		(178,557)
Loss before income taxes	$	(160,152)	$	(175,330)	$	(159,071)

Schedule of Components of Income Tax Expense (Benefit)

The provision for (benefit from) income taxes consisted of the following (in thousands):

	Fiscal Year Ended January 31,
	2024		2023		2022
Current:
Federal and State	$	(1,768)	$	1,432	$	(863)
Foreign	256,296		822		671
Total current	$	254,528	$	2,254	$	(192)
Deferred:
Federal and State	$	(810)	$	614	$	(1,443)
Foreign	10,339		30		124
Total deferred	$	9,529	$	644	$	(1,319)
Provision for (benefit from) income taxes	$	264,057	$	2,898	$	(1,511)

Schedule of Effective Income Tax Rate Reconciliation

A reconciliation of the statutory U.S. federal income tax rate to the Company's effective tax rate is as follows:

	Fiscal Year Ended January 31,
	2024		2023		2022
Tax at federal statutory rate	21.0	%	21.0	%	21.0	%
State, net of federal benefit	(0.1)		(0.2)		0.2
Stock-based compensation	2.4		(0.4)		5.0
Non-deductible Executive Compensation	(4.8)		(1.6)		(0.5)
Research tax credit	6.3		2.7		1.0
Foreign rate differential	(1.8)		5.5		6.1
Change in valuation allowance	(83.5)		(29.0)		(30.3)
Foreign derived intangible income deduction	—		0.6		0.3
Unrecognized tax benefits	(104.9)		(0.5)		(1.3)
Other	0.5		0.2		(0.6)
Total	(164.9)	%	(1.7)	%	0.9	%

Schedule of Deferred Tax Assets and Liabilities

Significant components of the Company's deferred tax assets and liabilities are as follows (in thousands):

	January 31,
	2024		2023
Deferred tax assets:
Net operating loss carryforwards	$	85,348	$	144,016
Research tax credits	14,031		2,359
Deferred revenue	6,812		5,876
Accruals and other assets	6,237		3,590
Capitalized R&D	70,921		—
Intangibles	110,160		8,278
Interest expense limitation	35,085		—
Stock-based compensation	6,679		5,040
Gross deferred tax assets	335,273		169,159
Valuation allowance	(328,385)		(159,470)
Net deferred tax assets	6,888		9,689
Deferred tax liabilities:
Deferred contract acquisition costs	(7,019)		(6,095)
Acquired intangibles	—		(863)
Equity method investment	—		(2,892)
Fixed assets	(191)		(499)
Unrealized foreign exchange adjustments	(10,024)		—
Other	(23)		(189)
Net deferred tax liabilities	$	(10,369)	$	(849)

Schedule of Unrecognized Tax Benefits Roll Forward

The reconciliation of the Company's unrecognized tax benefits is as follows (in thousands):

	January 31,
	2024		2023
Beginning balance	$	7,460	$	5,557
Gross increases due to tax positions taken in prior periods	324,364		685
Gross increases due to tax position taken in current period	65,001		1,369
Gross decreases due to lapses in applicable statutes of limitations	(1)		(151)
Ending balance	$	396,824	$	7,460